PET/MRI for neurological applications

PET/MRI for neurological applications

  1. Cognitive disorders and neurodegenerative diseases


  1. F-FDG - evaluation of local glucose metabolism in brain tissue, which could indicate the impairment of neuronal functions specific to particular types of dementia


  1. F-florbetapir/ 18F-florbetaben/ 18F-flutemetamol/11C-PiB - imaging of β-amyloid deposits in the brain in adult patients with cognitive impairment, diagnosed with suspected Alzheimer's disease (AD) and other conditions lead to a deterioration of cognitive abilities.

A negative result indicates the presence of a small amount or complete lack of neuritic plaques, which is not typical of AD and reduces the likelihood of AD being the cause of cognitive impairment in the patient.

The presence of β-amyloid deposits in the grey matter can be observed in elderly patients who are showing no symptoms of the disease, and in the case of dementia resulting from certain neurodegenerative diseases (Alzheimer's disease, dementia with Levy bodies, dementia in Parkinson's disease).


  1. Brain tumors


  1. F-FET, 11C-methionine (amino acid transport imaging)
  2. F-FLT (cellular proliferation imaging)
  3. F-MISO (hypoxia marker)
  4. F-FDG – the indication of hightened FDG accumulation does not have a good prognosis and is characteristic for undifferentiated tumors with high malignancy

- diagnostics of primary tumors and metastatic tumors

- suspicion of recurrence after treatment of primary tumors

- planning the radiotherapy of primary and metastatic tumors

- Planning a brain tumor biopsy in order to identify the most active part of the tumor

- Differentiation between the necrotic mass with the remaining part of the tumor, for example after surgery and radiotherapy


  1. Epilepsy


  1. F-FDG - localization of the focus of the seizures, especially in drug-resistant epilepsy, also to qualify the patient for surgery

The procedure helps to indicate the hypermetabolic focus in the ictal phase (middle phase), or the part with lower glucose metabolism between seizures.


  1. Parkinson's disease, Huntington's disease


  1. F-FDG – evaluation of glucose metabolism in brain tissue which shows its activity and neuronal dysfunction


  1. F-DOPA – assessment of dopaminergic transmission (neuronal ending function) in the striatum and substantia nigra


  1. Ischemic stroke, cerebral blood flow disorders


  1. O-H2O - radiopharmaceutical that enables cerebral blood flow imaging
  2. F-FDG – evaluation of local glucose metabolism in brain tissue which shows its activity


  1. Psychiatry


  1. F-FDG – evaluation of local glucose metabolism in brain tissue which shows its activity


Neurotransmission imaging, including dopaminergic and serotonergic neurotransmission, with the use of specific radiopharmaceuticals (11C-raclopride, 18F-DOPA,